newsfilter
← Latest News
GlobeNewswire·

Olema Oncology Reports Second Quarter 2025 Financial and Operating Results

Selected 90 mg once-daily palazestrant for Part 2 of the OPERA-01 Phase 3 monotherapy trial and for the OPERA-02 Phase 3 trial in combination with ribociclibOPERA-01 enrollment ongoing with top-line data expected in the